Your browser doesn't support javascript.
loading
The relationship between IL-10 levels and cardiovascular events in patients with CKD.
Yilmaz, Mahmut Ilker; Solak, Yalcin; Saglam, Mutlu; Cayci, Tuncer; Acikel, Cengizhan; Unal, Hilmi Umut; Eyileten, Tayfun; Oguz, Yusuf; Sari, Sebahattin; Carrero, Juan Jesus; Stenvinkel, Peter; Covic, Adrian; Kanbay, Mehmet.
Afiliação
  • Yilmaz MI; Departments of Nephrology.
  • Solak Y; Department of Medicine, Division of Nephrology, Karaman State Hospital, Karaman, Turkey;
  • Saglam M; Radiology.
  • Cayci T; Biochemistry, and.
  • Acikel C; Epidemiology, Gülhane School of Medicine, Ankara, Turkey;
  • Unal HU; Departments of Nephrology.
  • Eyileten T; Departments of Nephrology.
  • Oguz Y; Departments of Nephrology.
  • Sari S; Radiology.
  • Carrero JJ; Department of Medicine, Division of Renal Medicine andCentres for Molecular Medicine and Gender Medicine, Karolinska Institute, Stockholm, Sweden;
  • Stenvinkel P; Department of Medicine, Division of Renal Medicine and.
  • Covic A; Nephrology Clinic, Dialysis and Renal Transplant Center, C.I. PARHON University Hospital and Grigore T. Popa University of Medicine, Iasi, Romania; and.
  • Kanbay M; Department of Medicine, Division of Nephrology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey drkanbay@yahoo.com.
Clin J Am Soc Nephrol ; 9(7): 1207-16, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24789549
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Cardiovascular disease is the leading cause of death in patients with CKD. IL-10 is considered an antiatherosclerotic cytokine. However, previous studies have failed to observe an association between IL-10 and cardiovascular disease in CKD. This study aimed to evaluate whether serum IL-10 levels were associated with the risk of cardiovascular events in CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Four hundred three patients with stages 1-5 CKD were followed for a mean of 38 (range=2-42) months for fatal and nonfatal cardiovascular events. IL-10 and IL-6 were measured at baseline together with surrogates of endothelial function (flow-mediated dilatation) and proinflammatory markers (high-sensitivity C-reactive protein and pentraxin-3). The association between IL-10 and flow-mediated dilatation through linear regression analyses was evaluated. The association between IL-10 and the risk of cardiovascular events was assessed with Cox regression analysis.

RESULTS:

IL-10, IL-6, high-sensitivity C-reactive protein, and pentraxin-3 levels were higher among participants with lower eGFR. Both fatal (25 of 200 versus 6 of 203 patients) and combined fatal and nonfatal (106 of 200 versus 23 of 203 patients) cardiovascular events were more common in patients with IL-10 concentration above the median. Flow-mediated dilatation was significantly lower in patients with higher serum IL-10 levels, but IL-10 was not associated with flow-mediated dilatation in multivariate analysis. Kaplan-Meier survival curves showed that patients with IL-10 below the median value (<21.5 pg/ml) had higher cumulative survival compared with patients who had IL-10 levels above the median value (log-rank test, P<0.001).

CONCLUSIONS:

IL-10 levels increase along with the reduction of kidney function. Higher serum IL-10 levels were associated with the risk of cardiovascular events during follow-up. We speculate that higher IL-10 levels in this context signify an overall proinflammatory milieu.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Interleucina-10 / Insuficiência Renal Crônica Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Interleucina-10 / Insuficiência Renal Crônica Idioma: En Ano de publicação: 2014 Tipo de documento: Article